




Precision Optics Corporation

NASDAQ: POCI

May 2026



Forward-Looking Statements

This presentation contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express the Company's intentions, beliefs, expectations, strategies, predictions or any other statements related to the Company's future activities or future events or conditions. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by the Company's management. These statements are not guarantees of future performances and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including those risks discussed in the Company's annual report on Form 10-K and in other documents that the Company files from time to time with the SEC. Any forward-looking statements speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this report, except as required by law.

Non-GAAP Financial Measures

In addition to financial results reported in accordance with accounting principles generally accepted in the United States of America ("GAAP"), the Company has provided the following non-GAAP financial measures in this release and the accompanying tables: adjusted EBITDA. Precision Optics uses this non-GAAP financial measures internally to facilitate period-to-period comparisons and analysis of its operating performance and liquidity, and believes they are useful to investors as a supplement to GAAP measures in analyzing, trending and benchmarking the performance and value of our business. However, these measures are not intended to be a substitute for those reported in accordance with GAAP. These measures may be different from non-GAAP financial measures used by other companies, even when similar terms are used to identify such measures.


In order to calculate these non-GAAP financial measures, the Company makes targeted adjustments to certain GAAP financial line items found on its Consolidated Statement of Operations, backing out non-recurring or unique items or items that the Company believe otherwise distort the underlying results and trends of the ongoing business. We have excluded the following items from one or more of our non-GAAP financial measures for the periods presented:

Selling, general and administrative expenses; operating expenses. The Company excludes a portion of SG&A expense and operating expenses related to transaction expenses related to acquisitions and financings. Acquisition-related expenses include transaction fees, due diligence costs and other direct costs associated with our acquisitions. These amounts are unrelated to our core performance during any particular period and are impacted by the timing of the acquisition. The Company excludes acquisition-related expenses from the Company's SG&A expense and total operating expenses to provide investors a method to compare our operating results to prior periods and to peer companies, as such amounts can vary significantly based on the frequency of acquisitions and the magnitude of acquisition expenses.

Adjusted EBITDA is a non-GAAP financial measure that we define as GAAP net income (loss), adjusted to exclude non-recurring transaction costs, depreciation and amortization, non-cash stock-based compensation, interest expense, and provision (benefit) for income taxes. We believe that the use of adjusted EBITDA is useful to investors and other users of the Company's financial statements in evaluating our operating performance because it provides them with an additional tool to compare business performance across companies and across periods. The Company uses adjusted EBITDA in conjunction with traditional GAAP operating performance measures as part of our overall assessment of our performance, for planning purposes, including the preparation of our annual operating budget, to evaluate the effectiveness of our business strategies and to communicate with our board of directors concerning our financial performance. Management does not place undue reliance on adjusted EBITDA as its only measure of operating performance. Adjusted EBITDA should not be considered as a substitute for other measures of financial performance reported in accordance with GAAP.

Enabling Next Generation Technologies


Precision Optics is a **VERTICALLY INTEGRATED OPTICS COMPANY** primarily focused on leveraging its proprietary **MICRO-OPTICS AND IMAGING TECHNOLOGIES** to the **HEALTHCARE** and **DEFENSE/AEROSPACE** industries by providing services ranging from new product concept through mass manufacture.



Business Model


▶ Business model driving rapid growth


- ▶ Work closely with key medical device and defense companies at the very early design stage of projects, lending the Company's expertise in proprietary micro-optics, 3D imaging, and digital imaging technologies
- ▶ Robust pipeline supporting future commercial production opportunities
- ▶ Maintain and update IP through internal and customer funded R&D



Revenue Ramp

FY End June




A close-up, low-angle shot of a white industrial robotic arm. The arm is positioned diagonally across the frame. At the end of the arm, a precision tool is emitting a thin, bright white beam of light. The background is a deep blue with some blurred mechanical parts visible. A dark blue rectangular box is overlaid on the left side of the image, containing white text. A thin yellow and brown horizontal line is at the bottom of the dark blue box.


**LEADER IN MICRO,
ULTRA-HIGH PRECISION,
DIGITAL IMAGING**

Differentiated Product Technology Offerings



Micro Optics




3D Imaging & Ultra-High Precision



Digital Imaging



MicroPrecision Optics





- ▶ Millimeter sized and smaller cameras with low manufacturing costs
- ▶ Small size can provide visualization for new procedures in new parts of the body and for existing procedures that are currently performed blind or with sub-optimal imaging. Facilitates the development of new surgical procedures that are currently impractical.
- ▶ Patented and patent pending approaches to fabricating opto-mechanical and opto-electronic systems
- ▶ Best-in-class technical organization with 25+ years of experience to design and fabricate components and systems at industry's smallest sizes
- ▶ Commercialized and development applications in medical device and defense industry
- ▶ Market driven by surgical community that is demanding smaller and more enhanced imaging systems for minimally invasive surgery
 - ▶ Brain, eye, ear, urology, cardiology/angiography, spine

3D Endoscopes and Ultra-High Precision



- ▶ One of only a handful of companies in the world to design and provide 3D endoscopes
- ▶ Precision Optics 3D endoscopes provide next generation optical imaging for minimally invasive surgical procedures, many employing medical robotic technology, by using the brain's natural ability to perceive depth, which is the third dimension, by viewing one's environment through two eyes.
- ▶ Best-in-class technical organization with 20+ years of experience with 3D technology, that can design and fabricate 3D endoscopes and imaging systems for most demanding next-generation robotic systems
- ▶ Competition amongst medical device companies is increasing with multiple companies now pursuing less expensive, procedure specific robotic systems.
- ▶ Same technology can be used for 4K, fluorescence, AR/VR systems which are growing in med device market

Digital Imaging Electronics and Systems



- ▶ With the growing movement towards CMOS sensors in next generation devices, imaging system electronics are becoming increasingly critical to creating optimal solutions to our customer's requirements.
- ▶ Our product development team has extensive experience developing visualization systems that are used in a variety of clinical applications.
- ▶ Technical capability and experience in design and manufacture of electronic systems required to support CMOS-based imaging and LED illumination.
- ▶ Broad technical resources to support integrated system development including Optical, Mechanical, Electrical, Systems and Process Engineering .
- ▶ Full system design capability including handheld devices (single-use and reusable) and console capital equipment.

Key Markets: POC Has Supported The Medical Device Market For Many Years

▶ MicroPrecision Optics


- ▶ Smaller imaging systems enabling next generation minimally invasive surgery

▶ 3D Endoscopes & Ultra-High Resolution

- ▶ Robotic Surgery
- ▶ 4K Imaging
- ▶ AR/VR, fluorescence

▶ Digital Imaging

- ▶ Full medical device systems
- ▶ Single use endoscopes (15-20% CAGR)




Red circles indicate current programs in production or development

Key Markets: POC Is Increasing Engagement with Defense / Aerospace

► SWaP (Size Weight and Power)

► Areas of Focus

- Satellite communications (15-25% CAGR)
- UAV/Drones
- Directed energy weapons



Recent Large Orders

▶ Single-Use Cystoscopy Program

Program leverages POC's technology to supply single-use endoscope assemblies used in a cystoscopy surgery system


- ▶ \$9 million production order announced in May 2024
- ▶ Production deliveries began in mid-2024
- ▶ Company estimates the following delivery schedule:
 - ▶ \$2.6 million in fiscal 2025
 - ▶ \$4.6 million in fiscal 2026
 - ▶ Remainder in the first half of fiscal 2027.
 - ▶ Current annual production rate ~\$8 million

▶ Top Tier Aerospace Program

Program leverages POC's proprietary manufacturing technology developed for high precision micro-optics systems




- ▶ Production ramp initiated mid-2024.
- ▶ Follow-on orders have been received on an ongoing basis since that time.
- ▶ Signed Main Purchase Agreement in April 2025
 - ▶ Minimum purchase commitments of nearly \$4 million per year through calendar 2026.
- ▶ Current annual production rate ~\$12 million

Digital Imaging Systems – Horizontally Integrated



Vertically Integrated Design to Manufacture

Broad Optical Capabilities All Under One Roof



Unity Platform




UNITY PLATFORMS BENEFITS

- Accelerated time to market
 - Reduced development costs
 - De-risk projects
 - Customization gets customers closer to your ideal design parameters
- ▶ Groundbreaking modular optical platform is set to transform the development and production of endoscopic imaging devices by significantly reducing costs, time to market, and project risks
 - ▶ Standard baseline CMOS endoscopic system with customization options based on existing or newly designed sub-components
 - ▶ A Platform Built on a Depth of Experience: Culmination of many years of research, development, and collaboration with key industry players
 - ▶ Revolutionizing the One Customer, One Device Approach: Unity flips this model on its head by delivering a robust, adaptable system that serves as a foundation for entire families of products.


Expanding Product Development Pipeline

Product	Feasibility Study	Prototype Design	Prototype Fabrication	Verification/Validation	Production	Industry	Subsegment	Customer
Multiple Mature "Legacy" Products						Medical Device	Multiple	Multiple
Cystoscope #1						Medical Device	Cystoscopy	Large Medical Device
Optics Components						Defense/Aerospace	Confidential	Top Tier Defense/Aerospace
Cardiovascular Endoscope						Medical Device	Cardiac	CardioFocus
Otoscopy Device #1						Medical Device	Otoscopy	Large Medical Device
Micro Optics Components						Defense/Aerospace	Confidential	Top Tier Defense/Aerospace
Laparoscope						Medical Device	Robotic Laparoscopy	Well-funded Startup
Micro Endoscope						Medical Device	Ophthalmology	Mid-Tier Medical Device
Ophthalmoscope #1						Medical Device	Ophthalmology	Large Medical Device
Ureteroscope						Medical Device	Urology	Mid-Tier Medical Device
Arthroscope #1						Medical Device	Arthroscopy	Mid-Tier Medical Device
ENT Scope						Medical Device	Ear, Nose and Throat	Well-funded Startup
Otoscopy Device #2						Medical Device	Otoscopy	Well-funded Startup
Borescope						Industrial	Borescope	Mid-Tier Industrial
Laparoscope						Medical Device	Laparoscopy	Large Medical Device
Arthroscope						Medical Device	Carpel Tunnel Arthroscopy	Mid-Tier Medical Device
Borescope #2						Defense/Aerospace	Jet Engine Borescope	Top-Tier Defense/Aerospace

Go Forward Strategy



Continue expansion of production lines




Advance pipeline projects to commercialization



Expand product development pipeline leveraging Unity Platform



Disciplined investments in sales and marketing, as well as technical capabilities




Expand and update production facilities



Look for strategic acquisitions to broaden the Company's existing capabilities


FINANCIALS




Financial Snapshot

FY End 6/30, \$ in millions


Revenue



Gross Margins




Adjusted EBITDA




Quarterly Financial Snapshot

Quarterly FY ends June


Revenue



Gross Margins



Adjusted EBITDA



Income Statement Highlights

	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	Q1	Q2	Q3	Q4	FY 2025	Q1	Q2	Q3
Revenues	9,923,356	10,674,907	15,678,248	21,044,467	19,104,349	4,197,053	4,526,907	4,185,968	6,181,342	19,091,269	6,680,823	7,367,837	8,708,631
Cost of Goods Sold	6,560,779	7,241,323	10,750,061	13,310,331	13,306,574	3,079,723	3,456,965	3,767,993	5,377,093	15,681,774	5,734,465	7,163,177	6,652,097
Gross Profit	3,362,576	3,433,584	4,928,187	7,734,136	5,797,775	1,117,330	1,069,942	417,975	804,249	3,409,495	946,358	204,660	2,056,534
Operating Expenses	4,785,559	4,339,158	6,442,078	8,372,684	8,522,109	2,364,271	1,979,963	2,456,260	2,010,842	8,811,337	2,541,613	1,946,989	2,120,996
Operating Income (Loss)	(1,422,983)	(905,574)	(1,513,891)	(638,548)	(2,724,334)	(1,246,941)	(910,021)	(2,038,285)	(1,206,593)	(5,401,842)	(1,595,255)	(1,742,329)	(64,462)
Other - Interest Expense	(1,001)	(5,302)	(159,538)	(218,927)	(225,108)	(64,306)	(59,660)	(58,476)	(44,577)	(227,019)	(41,775)	(38,462)	(35,116)
Other Income	-	808,962	745,963	714,798	-	-	-	-	-	-	-	-	-
Income Tax	(2,165)	(912)	(952)	(1,936)	(1,936)	-	-	-	-	-	-	-	8,705
Net Income (Loss)	(1,426,149)	(102,826)	(928,418)	(144,613)	(2,949,442)	(1,311,247)	(969,681)	(2,096,761)	(1,251,170)	(5,628,861)	(1,637,030)	(1,780,791)	(108,283)
Stock Comp & Services Expense	547,345	733,930	915,494	919,032	959,784	149,364	308,206	714,662	288,478	1,460,710	301,639	187,081	253,778
Business Acquisition Expenses	-	-	162,125	-	-	-	-	-	-	-	-	-	-
Other Income	-	(808,962)	(742,052)	(714,798)	-	-	-	-	-	-	-	-	-
Depreciation & Amortization	112,218	146,926	190,068	210,735	212,382	48,290	46,338	58,585	60,263	213,476	65,181	74,165	75,602
Interest Expense	1,001	5,302	159,538	218,927	225,108	64,306	59,660	58,476	44,577	227,019	41,775	38,462	35,116
Income Taxes	2,165	912	952	1,936	1,936	-	-	-	-	-	-	-	8,705
Adjusted EBITDA	(763,419)	(24,718)	(242,293)	491,219	(1,552,168)	(1,049,287)	(555,478)	(1,261,265)	(857,852)	(3,727,656)	(1,228,435)	(1,481,083)	264,918

Balance Sheet Highlights

	6/30/2020	6/30/2021	6/30/2022	6/30/2023	6/30/2024	6/30/2025	3/31/2026
Cash and cash equivalents	\$1,134,697	\$861,650	\$605,749	\$2,925,852	\$405,278	\$1,773,735	\$10,680,046
Accounts receivable, net	\$1,481,437	\$1,878,755	\$2,663,872	\$3,907,407	\$3,545,491	\$4,336,730	\$6,577,866
Inventory	\$2,197,244	\$1,885,395	\$3,079,938	\$2,776,216	\$2,868,100	\$3,562,112	\$3,702,461
Total assets	\$6,351,531	\$6,261,300	\$16,704,020	\$19,740,434	\$16,912,574	\$19,790,287	\$33,686,207
Current Liabilities	\$3,149,380	\$2,511,110	\$4,586,641	\$5,259,620	\$4,906,816	\$6,151,294	\$10,192,919
Acquisition earn out liability (incl. current portion)	\$500,000	\$333,333	\$872,559	\$0	\$0	\$0	\$0
Bank Debt (incl. current portion)	\$0	\$0	\$2,328,855	\$2,689,239	\$2,175,980	\$1,867,103	\$1,433,678
Total shareholder's equity	\$2,771,761	\$3,431,127	\$8,971,495	\$12,046,592	\$10,067,788	\$12,258,834	\$20,105,907
Shares Outstanding*	4,397,263	4,427,492	5,638,363	6,066,518	6,073,939	7,714,701	10,929,869

*Reflects 1-for-3 split enacted on November 2, 2022



THANK YOU